TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Update

TherapeuticsMD, Inc. (NASDAQ:TXMD) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 240,200 shares, a growth of 1,901.7% from the December 31st total of 12,000 shares. Based on an average daily trading volume, of 286,000 shares, the short-interest ratio is currently 0.8 days. Currently, 2.1% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of TherapeuticsMD in a report on Tuesday, January 14th. They issued a “hold” rating for the company.

TherapeuticsMD Stock Performance

TXMD stock remained flat at $1.08 during mid-day trading on Friday. 12,606 shares of the company’s stock were exchanged, compared to its average volume of 854,330. The stock has a 50-day moving average of $1.18 and a two-hundred day moving average of $1.49. TherapeuticsMD has a 52 week low of $0.70 and a 52 week high of $2.75.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.05) EPS for the quarter. The business had revenue of $0.55 million for the quarter. TherapeuticsMD had a negative return on equity of 14.08% and a negative net margin of 207.77%.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.